As Spring Season Starts, ThumbPRO Reminds of Proactive Hand Safety Measures
Concord, MA - March 14, 2025 - ThumbPRO®, a trusted thumb protector designed to safeguard all athletes, including youth athletes, from hand injuries caused by bat vibration, reminds parents, coaches, and youth baseball and softball players to prioritize proactive hand safety measures as the spring season commences. The company emphasizes that preventative steps are crucial to help avoid common hand injuries that can sideline athletes.
Youth baseball and softball players are particularly susceptible to hand injuries during the spring season. The combination of increased practice intensity, the return to competitive play, and the developing nature of young athletes' hands creates a heightened risk from injury due to bat vibration. ThumbPRO®'s mission is to empower parents, coaches, and players with the knowledge and tools to protect against these injury risks.
'Spring training and the start of the season are exciting times, but it's crucial to remember that proactive protection is essential for every player and every player should have access to safety gear at the plate,' says Nina Nickles, CEO of ThumbPRO®. 'Hand injuries can sideline all baseball and softball players, including young athletes. For youth athletes, in particular, these types of hand injuries can disrupt their development, along with their confidence at the plate and their passion for the game. By incorporating preventative measures, such as using ThumbPRO®'s protective thumb guards, players can confidently step up to the plate.'
ThumbPRO®'s thumb protectors are designed to mitigate bat sting, help prevent common hand injuries, and enhance grip, providing crucial protection without hindering performance. The ergonomic design ensures comfort and stability, allowing players to focus on their game.
Key Points for Proactive Hand Safety:
Consistent Use of Protective Gear: ThumbPRO® recommends consistently using protective thumb guards during practices and games to help reduce the risk of impact injuries.
Proper Warm-Up and Stretching: Emphasizing the importance of thorough warm-ups and stretching to prepare hands and wrists for physical activity.
Awareness and Technique: Educating young athletes on proper batting techniques to minimize the risk of hand injuries from bat vibration and impact.
Early Intervention: Encourage parents and coaches to address any signs of hand discomfort or injury promptly.
'By prioritizing hand safety, we help ensure all athletes, including young athletes, enjoy a successful and injury-free season while at bat,' Nickles adds. 'ThumbPRO® is committed to providing reliable protective gear and promoting a safety-first mindset.'
To support proactive hand safety, ThumbPRO® is offering special spring-season promotions, including bundle discounts and free US shipping on select orders. Visit www.baseballthumbguard.com to learn more.
About ThumbPRO®
ThumbPRO® is a USA based company dedicated to the safety and well-being of all baseball and softball players, including youth athletes. The company designs its thumb protectors to help prevent bat sting and to help avoid common hand injuries. As a family-owned enterprise, ThumbPRO® prioritizes player safety by producing high-quality, comfortable, protective equipment trusted by the pros as well as parents, coaches, and athletes at all levels of play. From youth players to professionals, injury prevention remains critical for sustained participation in the game. ThumbPRO® thumb protectors enhances player safety by helping to reduce the risk of hand injuries caused by sustained bat vibration. As sports protective equipment continues to evolve, ThumbPRO® stands for and with all players — regardless of age or level—to have equal access to safety gear that helps them remain safe, enabling them to perform at their very best with confidence at the plate season after season.
Media Contact

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Fungi concerns spark nationwide recall of Zicam® and Orajel™ products
(WJW) – According to the U.S. Food and Drug Administration, Church & Dwight Co., Inc. is voluntarily recalling some Zicam® and Orajel™ products because fungi could be present in the items' cotton swab components. The recalled products include all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. Consumers are advised to 'immediately' stop using the recalled products. Major grocery chain slashing prices for the summer 'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA. Brain-eating amoeba: How are people infected? Here's the specific details to check for: Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. You can view images of the recalled products in the slideshow below: 'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website. Consumers can CLICK HERE or call (800) 981-4710 for refund details. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Business Wire
33 minutes ago
- Business Wire
Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health today announced extensive updates to its Sentri7 ® Drug Diversion and Sentri7 ® Pharmacy solutions, reinforcing its commitment to innovation in medication safety, compliance, and patient care. These improvements further equip clinical teams with actionable, data-driven insights to streamline workflows for drug diversion and medication management, ultimately supporting better patient care. 'Our mission is to help healthcare organizations deliver safer, higher-quality care with solutions that optimize the workflows supporting patient care and compliance in today's demanding healthcare environment,' said Karen Kobelski, Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions at Wolters Kluwer Health. " With our team's deep expertise in pharmacy, technology, and artificial intelligence, we're providing customers with critical insights and support to address challenges like medication management, drug diversion prevention, and the opioid crisis.' Sentri7 Drug Diversion delivers improved workflows The redesigned Sentri7 Drug Diversion solution introduces a more intuitive interface, enabling teams to detect and manage drug diversion threats with greater precision and efficiency. Healthcare organizations can now act faster and more effectively to mitigate risks, with features like: User-friendly dashboard: Consolidates essential risk factors and actionable insights into a single, user-friendly interface to streamline diversion detection follow-up. Refined HEAT™ scoring and trend analysis: Quickly identifies high-risk staff across multiple facilities with a Watch List that improves alert monitoring of priority areas of concern. Missing medication analysis: Saves time for busy nursing teams by reconciling medication transactions across care areas, enabling timely interventions. 'Sentri7 Drug Diversion has a very mature user interface. It is very straightforward. It is easy to use and train our diversion staff to use. The graphics are very clear to understand. The solution has a HEAT score that it gives when it suspects an employee of diversion. It promotes that information to us and tells us where there is suspicious activity rather than us having to look at the numbers and determine that on our own,' according to a pharmacy manager interviewed by KLAS Research, February 2025. Sentri7 Pharmacy updates support patient-centered care The updated Sentri7 Pharmacy solution delivers an efficient, patient-centric workflow to optimize medication therapies, safety and overall cost savings. Key updates include: User-friendly interface: Tailored to support rounding workflows for individual patients, in addition to managing targeted medication surveillance across the entire patient population. Enhanced documentation tools: Simplified and standardized data entry enhances reporting, enabling pharmacy teams to demonstrate impact with evidence-based metrics. Actionable Performance Insights: Provides clear key performance indicators on cost savings, departmental contributions, and patient outcomes. When asked about Wolters Kluwer's surveillance solution, one pharmacy analyst noted in a KLAS Research April 2025 interview, 'Wolters Kluwer is super engaging and allows for a lot of collaborative work with organizations. The vendor does a good job of meeting organizations where they are at and working toward solutions. Wolters Kluwer has just been great at engaging with end users on how to improve their Sentri7 Pharmacy Surveillance product. I would definitely recommend Sentri7 Pharmacy Surveillance.' Learn more about the enhanced Sentri7 solutions. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Yahoo
2 hours ago
- Yahoo
Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery
Partnership combines AI-powered protein manufacturing with advanced drug delivery technologies to accelerate timelines and improve therapeutic outcomes. MADISON, Wis. and KANSAS CITY, Mo., June 9, 2025 /PRNewswire/ -- Axio BioPharma Inc., a next-generation biomanufacturing company using AI to transform mammalian protein production, and Likarda Inc., a leader in advanced drug delivery and formulation technologies, today announced a strategic partnership to accelerate innovation in biologic drug development. This collaboration will integrate Likarda's proprietary delivery technologies with Axio's manufacturing capabilities, creating a more efficient and scalable path to clinical manufacturing for clients across the biopharmaceutical sector. Through this collaboration, Axio BioPharma will incorporate Likarda's proprietary delivery platforms— including its Core-Shell Spherification® (CSS®) hydrogel technology for encapsulation, stability, and controlled release —into its service offering, enhancing workflows for monoclonal antibodies (mAbs), bispecifics, and Fc-fusions. Likarda will also offer Axio's discovery-to-GMP manufacturing capabilities to its client base, supporting programs in need of high-quality protein production and scalable manufacturing solutions. "This partnership brings delivery innovation directly into the development process, helping our clients move faster and make better decisions," said Justin Byers, CEO of Axio BioPharma. "By aligning earlier on both delivery and manufacturing, we reduce friction, shorten timelines, and provide integrated solutions that truly support our clients' goals." "At Likarda, we believe that delivery should never be an afterthought—it should be part of the development strategy from day one," said Dr. Stella Vnook, CEO of Likarda Inc. "Partnering with Axio allows us to integrate our encapsulation and formulation technologies earlier in the drug development process, where they can have the greatest impact on stability, efficacy, and patient experience. Importantly, it provides seamless integration to scaled manufacturing for our clients. Together, we're creating a smarter, more connected path from discovery to clinic." This collaboration strengthens Axio's mission of transforming biologic manufacturing through predictive science and digital-first process development. At the same time, it enables Likarda to apply its proprietary delivery technologies earlier in the development cycle, giving clients new efficiencies and expanded therapeutic applications. For partnership inquiries or media contact, please reach out to: Madelyn De Los SantosSenior Advisor, Putnam InsightsMadelyn@ OR Shelly AdamsCCO, Likarda, About Axio BioPharmaAxio BioPharma is an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Headquartered in Madison, WI, Axio combines high-throughput experimentation with proprietary machine learning to predict optimal manufacturing processes in hours—not years. By accelerating development timelines and reducing costs, Axio enables biopharma innovators to bring life-saving therapies to market faster and more efficiently. With deep expertise in antibody manufacturing, protein purification, and bioinformatics, Axio supports a wide range of partners across research, diagnostics, and therapeutics with scalable, U.S.-based production and data-enhanced process design. About Likarda Likarda is revolutionizing the delivery of cell therapies, biologics, and small molecules, making these life-changing treatments accessible to more patients with chronic and life-threatening diseases. At the core of Likarda's innovation is Core-Shell Spherification® (CSS®), a highly customizable polymer-based delivery platform. This cutting-edge technology ensures therapeutics are protected, precisely delivered, and retained at their target—whether it's the tumor microenvironment, sites of organ degeneration, or other critical areas. By enabling targeted, sustained release, Likarda's solutions enhance therapeutic efficacy while reducing off-target effects and improving patient outcomes. The platform's versatility supports a range of applications, from immune protection in cell therapy to extended-release biologics, paving the way for next-generation treatments across oncology, regenerative medicine, and other disease areas. With a commitment to innovation, scalability, and accessibility, Likarda is poised to transform drug delivery and expand the reach of advanced therapies. To learn more, visit View original content: SOURCE Axio BioPharma Inc.